Holen Sie sich die Stockscreener-App
75.70
0.60%
0.41
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt EW?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$75.29
Offen:
$75.09
24-Stunden-Volumen:
839.08K
Relative Volume:
0.20
Marktkapitalisierung:
$44.46B
Einnahmen:
$5.69B
Nettoeinkommen (Verlust:
$1.41B
KGV:
10.84
EPS:
6.9828
Netto-Cashflow:
$577.90M
1W Leistung:
+3.24%
1M Leistung:
+1.79%
6M Leistung:
+9.45%
1J Leistung:
+8.12%
1-Tages-Spanne:
$74.69
$75.83
1-Wochen-Bereich:
$72.40
$75.83
52-Wochen-Spanne:
$64.89
$83.00
Edwards Lifesciences Corp Stock (EW) Company Profile
Firmenname
Edwards Lifesciences Corp
Sektor
Branche
Telefon
(949) 250-2500
Adresse
ONE EDWARDS WAY, IRVINE, CA
Vergleichen Sie EW mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
75.72 | 44.20B | 5.69B | 1.41B | 577.90M | 6.9828 |
|
ABT
Abbott Laboratories
|
128.44 | 225.41B | 43.84B | 13.94B | 6.78B | 7.9979 |
|
BSX
Boston Scientific Corp
|
99.61 | 148.96B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
378.60 | 145.74B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
95.84 | 123.04B | 34.20B | 4.69B | 5.30B | 3.6218 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-10-07 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-07-29 | Hochstufung | BTIG Research | Neutral → Buy |
| 2025-04-24 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | Hochstufung | Stifel | Hold → Buy |
| 2025-01-16 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-09-18 | Herabstufung | Jefferies | Buy → Hold |
| 2024-07-31 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-07-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-07-25 | Herabstufung | Truist | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-05-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-03-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-02-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-11-28 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-03-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | Herabstufung | Bernstein | Outperform → Underperform |
| 2023-01-30 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | Herabstufung | Stifel | Buy → Hold |
| 2022-10-28 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-10-26 | Eingeleitet | Mizuho | Buy |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-29 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | Eingeleitet | Truist | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-03-16 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-27 | Bestätigt | Citigroup | Buy |
| 2022-01-27 | Bestätigt | Evercore ISI | Outperform |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Buy |
| 2022-01-27 | Bestätigt | UBS | Neutral |
| 2021-12-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-12-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | Bestätigt | Canaccord Genuity | Buy |
| 2021-07-30 | Bestätigt | Deutsche Bank | Hold |
| 2021-07-30 | Bestätigt | Jefferies | Buy |
| 2021-07-30 | Bestätigt | Morgan Stanley | Overweight |
| 2021-07-30 | Bestätigt | Oppenheimer | Outperform |
| 2021-07-30 | Bestätigt | Stifel | Buy |
| 2021-07-30 | Bestätigt | UBS | Neutral |
| 2021-07-30 | Bestätigt | Wells Fargo | Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-04-05 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-11 | Bestätigt | Canaccord Genuity | Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Underperform |
| 2020-04-28 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Outperform |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-10-24 | Bestätigt | Canaccord Genuity | Buy |
| 2019-09-23 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-24 | Bestätigt | BofA/Merrill | Buy |
| 2019-03-18 | Bestätigt | Canaccord Genuity | Buy |
| 2019-01-18 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | Eingeleitet | Deutsche Bank | Hold |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-16 | Eingeleitet | Barclays | Underweight |
| 2018-10-02 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | Herabstufung | Guggenheim | Buy → Neutral |
Alle ansehen
Edwards Lifesciences Corp Aktie (EW) Neueste Nachrichten
Piper Sandler Maintains Overweight on Edwards Lifesciences (EW) Ahead of PARTNER 3 7-Year Results - Yahoo
Is Edwards Lifesciences Corporation (EWL) stock resilient in recession scenariosJuly 2025 Final Week & Growth-Oriented Investment Plans - newser.com
Quantitative breakdown of Edwards Lifesciences Corporation recent moveJuly 2025 Short Interest & Weekly Top Gainers Alerts - newser.com
How Edwards Lifesciences Corporation stock reacts to new regulationsQuarterly Profit Summary & High Conviction Buy Zone Picks - newser.com
How Edwards Lifesciences Corporation (EWL) stock responds to bond marketRecession Risk & Low Risk Entry Point Tips - newser.com
Using portfolio simulators with Edwards Lifesciences Corporation includedJuly 2025 Fed Impact & Stepwise Trade Signal Guides - newser.com
Is Edwards Lifesciences Corporation stock cheap by valuation metricsTrend Reversal & Safe Entry Momentum Tips - newser.com
Edwards Lifesciences Corporation stock prediction for this week2025 Price Momentum & Scalable Portfolio Growth Methods - newser.com
Can Edwards Lifesciences Corporation stock survive global slowdownWeekly Trend Recap & Verified Stock Trade Ideas - newser.com
Why Edwards Lifesciences Corporation stock remains on buy listsJuly 2025 Outlook & Verified Swing Trading Watchlists - nchmf.gov.vn
Will Edwards Lifesciences Corporation stock return to pre crisis levelsTake Profit & Safe Swing Trade Setups - nchmf.gov.vn
Published on: 2025-10-18 04:03:36 - nchmf.gov.vn
Gains Report: Is Edwards Lifesciences Corporation stock supported by strong cash flowsTrend Reversal & Free Expert Approved Momentum Trade Ideas - nchmf.gov.vn
Edwards Lifesciences (EW) Added to Evercore ISI's Tactical Outpe - GuruFocus
Robust TAVR Growth to Drive Edwards Lifesciences' Q3 Earnings - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (GDRX) and Edwards Lifesciences (EW) - The Globe and Mail
Using Python tools to backtest Edwards Lifesciences Corporation strategiesQuarterly Earnings Summary & Real-Time Volume Analysis - newser.com
EW Investor News: Rosen Law Firm Investigates Breaches of Fiduciary Duties by the Directors and Officers of Edwards Lifesciences Corporation – EW - GlobeNewswire Inc.
How high can Edwards Lifesciences Corporation stock goIndex Update & Proven Capital Preservation Methods - newser.com
Is Edwards Lifesciences Corporation stock a good choice for value investorsVolume Spike & Community Verified Swing Trade Signals - newser.com
Leerink Partners Adjusts Price Target on Edwards Lifesciences to $84 From $85, Maintains Market Perform Rating - MarketScreener
Mizuho Adjusts Price Target on Edwards Lifesciences to $90 From $95, Maintains Outperform Rating - MarketScreener
Oversold Conditions For Edwards Lifesciences (EW) - Nasdaq
What is the fair value of Edwards Lifesciences Corporation stock nowWeekly Market Outlook & Target Return Focused Stock Picks - newser.com
Aberdeen Group plc Increases Position in Edwards Lifesciences Corporation $EW - MarketBeat
OFI Invest Asset Management Has $26.57 Million Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Stonehage Fleming Financial Services Holdings Ltd Makes New Investment in Edwards Lifesciences Corporation $EW - MarketBeat
Callan Family Office LLC Boosts Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
EW Investor News: Rosen Law Firm Investigates Breaches of - GlobeNewswire
Real time breakdown of Edwards Lifesciences Corporation stock performanceGDP Growth & Weekly Market Pulse Updates - newser.com
Ranking Edwards Lifesciences Corporation among high performing stocks via toolsPortfolio Risk Summary & Low Drawdown Momentum Trade Ideas - newser.com
Blair William & Co. IL Has $30.51 Million Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
What machine learning models say about Edwards Lifesciences CorporationWeekly Trade Report & Weekly Breakout Watchlists - newser.com
Visual trend scoring systems applied to Edwards Lifesciences Corporation2025 Analyst Calls & Reliable Volume Spike Alerts - newser.com
Vontobel Holding Ltd. Reduces Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences (EW): Assessing Valuation Following Recent Share Price Decline - Yahoo Finance
Edwards Lifesciences (NYSE:EW) Given "Hold (C)" Rating at Weiss Ratings - MarketBeat
Here's What to Expect From Edwards Lifesciences’ Next Earnings Report - MSN
Edwards Lifesciences Leads Healthcare Stocks in S&P 500 - Kalkine Media
Edwards Lifesciences' Long-Term Plan Raises Concerns Amid 'Structural' Risks, Oppenheimer Says - MarketScreener
Edwards Lifesciences (NYSE:EW) Upgraded at Evercore ISI - MarketBeat
Edwards Lifesciences stock downgraded by Oppenheimer on structural concerns - Investing.com
Oppenheimer Downgrades Edwards Lifesciences to Market Perform From Outperform - MarketScreener
Edwards Lifesciences Corporation $EW Shares Bought by Mirova US LLC - MarketBeat
Shell Asset Management Co. Acquires 19,014 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences (EW) Upgraded by Evercore ISI - GuruFocus
Edwards Lifesciences (EW) Receives Analyst Upgrade and Price Tar - GuruFocus
Edwards Lifesciences stock maintains Overweight rating ahead of PARTNER 3 data - Investing.com
Edwards Lifesciences stock upgraded by Evercore ISI on reduced competition - Investing.com
Evercore ISI Upgrades Edwards Lifesciences to Outperform From In Line, Adjusts PT to $88 From $80 - MarketScreener
Seamount Financial Group Inc. Invests $259,000 in Edwards Lifesciences Corporation $EW - MarketBeat
Finanzdaten der Edwards Lifesciences Corp-Aktie (EW)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.95%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):